NCM
ACET icon

NEXTBio Capital Management’s Adicet Bio ACET Stock Holding History

NEXTBio Capital Management’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Hold
157,827
– – 0.63% 22
2026
Q1 		$1.07M Hold
157,827
– – 0.5% 24
2025
Q4 		$1.33M Buy
+157,827
New +$1.74M 0.78% 23

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return

NEXTBio Capital Management's ACET Position: Q2 2026 in Review

NEXTBio Capital Management held its Adicet Bio (ACET) position steady in Q2 2026 at 157,827 shares worth $1.36M. The position accounts for 0.63% of the portfolio, ranked #22.

NEXTBio Capital Management first reported a position in ACET in Q4 2025 and has held it in 3 quarters since. 56 funds tracked by Wall St. Rank hold ACET as of Q2 2026.

  • NEXTBio Capital Management held 157,827 shares of Adicet Bio worth $1.36M as of Q2 2026.
  • NEXTBio Capital Management left its Adicet Bio share count unchanged in Q2 2026.
  • Adicet Bio made up 0.63% of NEXTBio Capital Management's portfolio in Q2 2026, its #22 holding.
  • NEXTBio Capital Management first reported a position in Adicet Bio in Q4 2025 and has held it in 3 quarters since.
  • 56 funds tracked by Wall St. Rank held Adicet Bio as of Q2 2026.

Based on NEXTBio Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.